PTIX
Protagenic Therapeutics, Inc.newPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Jul 30 to Aug 11 ▲ 4 days of insider buys: $7.0K by 1 insider, avg $0.2036
- Aug 19 to Aug 21 ▲ 3 days of insider buys: $23.8K by 1 insider, avg $0.6039
- Aug 20 ▲ Protagenic Therapeutics received written FDA pre-IND feedback for it…
Signal stack
Where each data set points today.
- InsidersBULLISH
1 insider bought $30.7K at an average $0.4177. No open-market sales. Price is 8% above their cost.
- InstitutionsMIXED
Q4 2025: 1 added (0 new), 1 trimmed or exited.
- Short sellersSTEADY
Short interest −0.3% to 12.9K shares. 6.6 days to cover.
- TrendDOWNTREND
39% below its 50-day average.
Who's buying
13F· Q4 2025| Fund | Move | Value |
|---|---|---|
| BANK OF AMERICA CORP /DE/ | DOUBLED | $22.00 |
| MORGAN STANLEY | NEAR_EXIT | $2.00 |
| CITIGROUP INC | DOUBLED | $6.1K |
| UBS Group AG | NEAR_EXIT | $192.00 |
| BANK OF AMERICA CORP /DE/ | ADD | $27.00 |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | $15.1K |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | $21.8K |
| UBS Group AG | ADD | $7.1K |
Quarterly 13F filings are due 45 days after each quarter ends.
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
ARMEN GARO H EXEC. CHAIR & PRINCIPAL OFF Aug 21, 2026 | BUY | $13.0K |
ARMEN GARO H EXEC. CHAIR & PRINCIPAL OFF Aug 20, 2026 | BUY | $9.8K |
ARMEN GARO H EXEC. CHAIR & PRINCIPAL OFF Aug 19, 2026 | BUY | $945.00 |
ARMEN GARO H EXEC. CHAIR & PRINCIPAL OFF Aug 11, 2026 | BUY | $710.40 |
ARMEN GARO H EXEC. CHAIR & PRINCIPAL OFF Aug 6, 2026 | BUY | $150.70 |
ARMEN GARO H EXEC. CHAIR & PRINCIPAL OFF Aug 5, 2026 | BUY | $1.3K |
ARMEN GARO H EXEC. CHAIR & PRINCIPAL OFF. Jul 30, 2026 | BUY | $4.8K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | None | None | No data | $0.00 |
| Next Q | None | None | No data | $0.00 |
| Current FY | None | None | No data | $0.00 |
| Next FY | None | None | No data | $0.00 |
Short side
FINRA· Oct 30, 2026SecBot reports
3 filings · 1 bullish · 1 bearish · 1 neutral- BEARISH 8-KNov 17, 2026
Protagenic Therapeutics entered into a securities purchase agreement to sell up to $3.0 million (expandable to $5.0 million) of common stock, pre-funded warrants, Series A and Series B common warrants in a private placement at $0.61 per share. The offering includes significant potential dilution…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 8-KNov 6, 2026
Protagenic Therapeutics issued a $250,000 promissory note to Patness LLC, bearing 1.0% simple…
The note's repayment trigger tied to a $1,000,000 equity raise suggests the company will likely pursue a capital raise within six months. Monitor for any equity offering announcement, which would…
- BULLISH 8-KAug 20, 2026
Protagenic Therapeutics received written FDA pre-IND feedback for its lead candidate PT00114 in…
This FDA pre-IND clearance removes a key regulatory de-risking event for PT00114, making the IND submission timeline (Q4 2026) the next catalyst. However, the company's penny stock status, limited…
All PTIX filing & press-release reports (3)
- 8-K reportNov 17, 2026
- 8-K reportNov 6, 2026
- 8-K reportAug 20, 2026